DOI: https://doi.org/10.14710/jbtr.v6i1.7321

Fragile X Syndrome and Targeted Treatments

1Prince of Songkla University, Thailand

2Universidad del Valle, Colombia

3UC Davis MIND Institute, United States

4 UC Davis School of Medicine, United States

View all affiliations
Received: 3 Mar 2020; Revised: 30 Mar 2020; Accepted: 31 Mar 2020; Available online: 30 Apr 2020; Published: 30 Apr 2020.
Open Access Copyright (c) 2020 Journal of Biomedicine and Translational Research

Citation Format:
Abstract

Many targeted treatment studies have been carried out in individuals with Fragile X Syndrome (FXS) guided by animal studies from the Fragile X Mental Retardation 1 (FMR1) knock out (KO) mice and the fragile X Drosophila studies. Here we review the many medications that have been studied in patients with FXS and some of these medications are available for clinical use by wise clinicians. Other medications are not currently available by prescription because they are not approved by the FDA. No medication has received specific approval for treatment of FXS, although some have shown benefit from clinical studies. There is much to be done in the treatment of those with FXS and this report describes those pharmacological treatments that target the neurobiological mechanisms that are dysregulated by the lack of the Fragile X Protein (FMRP) in those with FXS.

Note: This article has supplementary file(s).

Fulltext View|Download |  Research Instrument
Untitled
Subject
Type Research Instrument
  Download (23KB)    Indexing metadata
Keywords: Fragile X syndrome, FMR1, targeted treatment

Article Metrics:

Article Info
Section: Review Articles
Language : EN
Recent articles
Randomized Controlled Trial of Tranexamic Acid’s Effect on Bleeding Length: A Study on DMPA Users with Abnormal Uterine Bleeding Who Receive Low-Dose Oral Contraceptive Pill Antioxidant and Elastase Inhibitor from Black Soybean (Glycine max L.) and Its Compound (Daidzein) Association of Growth Velocity with Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 Levels in Children with a Vegan Diet Unraveling of Diagnosis Odyssey in A Girl with Primary Amenorrhea: A case report Fragile X Syndrome and Targeted Treatments More recent articles
  1. Hanson AC, Hagerman RJ. Serotonin dysregulation in fragile X syndrome: implications for treatment. Intractable Rare Dis Res 2014;3:110–7
  2. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers 2017;3:17065
  3. Gantois I, Popic J, Khoutorsky A, Sonenberg N. Metformin for treatment of fragile X syndrome and other neurological disorders. Annu Rev Med 2019;70:167–81
  4. Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K, et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011;124:3369–80
  5. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086–91
  6. van Dalem J, Brouwers MCGJ, Stehouwer CDA, Krings A, Leufkens HGM, Driessen JHM, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ 2016;354:i3625
  7. Monyak RE, Emerson D, Schoenfeld BP, Zheng X, Chambers DB, Rosenfelt C, et al. Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model. Mol Psychiatry 2017;22:1140–8
  8. Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med 2017;23:674–7
  9. Dy ABC, Tassone F, Eldeeb M, Salcedo-Arellano MJ, Tartaglia N, Hagerman R. Metformin as targeted treatment in fragile X syndrome. Clin Genet 2018;93:216–22
  10. Biag HMB, Potter LA, Wilkins V, Afzal S, Rosvall A, Salcedo-Arellano MJ, et al. Metformin treatment in young children with fragile X syndrome. Mol Genet Genomic Med 2019;7:e956
  11. Anagnostou E, Aman MG, Handen BL, Sanders KB, Shui A, Hollway JA, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2016;73:928–37
  12. Handen BL, Anagnostou E, Aman MG, Sanders KB, Chan J, Hollway JA, et al. A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young People with autism spectrum disorder: open-label extension. J Am Acad Child Adolesc Psychiatry 2017;56:849-856.e6
  13. Aman MG, Hollway JA, Veenstra-VanderWeele J, Handen BL, Sanders KB, Chan J, et al. Effects of metformin on spatial and verbal memory in children with ASD and overweight associated with atypical antipsychotic use. J Child Adolesc Psychopharmacol 2018;28:266–73
  14. Schneider A, Ligsay A, Hagerman RJ. Fragile X syndrome: an aging perspective. Dev Disabil Res Rev 2013;18:68–74
  15. Protic D, Aydin EY, Tassone F, Tan MM, Hagerman RJ, Schneider A. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. Mol Genet Genomic Med 2019;7:e00745
  16. Protic D, Kaluzhny P, Tassone F, Hagerman RJ. Prepubertal metformin treatment in fragile X syndrome alleviated macroorchidism: a case study. Adv Clin Transl Res 2019;3:100021
  17. Bilousova T V, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009;46:94–102
  18. Siller SS, Broadie K. Neural circuit architecture defects in a Drosophila model of fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 2011;4:673–85
  19. Yau SY, Bettio L, Vetrici M, Truesdell A, Chiu C, Chiu J, et al. Chronic minocycline treatment improves hippocampal neuronal structure, NMDA receptor function, and memory processing in Fmr1 knockout mice. Neurobiol Dis 2018;113:11–22
  20. Toledo MA, Wen TH, Binder DK, Ethell IM, Razak KA. Reversal of ultrasonic vocalization deficits in a mouse model of fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9. Behav Brain Res 2019;372:112068
  21. Leigh MJS, Nguyen D V, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 2013;34:147–55
  22. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SMH, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010;115:433–43
  23. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10:91
  24. Protic D, Salcedo-Arellano MJ, Dy JB, Potter LA, Hagerman RJ. New targeted treatments for fragile X syndrome. Curr Pediatr Rev 2019;15:251–8
  25. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: a retrospective chart review. Autism Res Treat 2012;2012:104317
  26. Sodhi MSK, Sanders-Bush E. Serotonin and brain development. Int Rev Neurobiol 2004;59:111–74
  27. Chandana SR, Behen ME, Juhász C, Muzik O, Rothermel RD, Mangner TJ, et al. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci 2005;23:171–82
  28. Lim C-S, Hoang ET, Viar KE, Stornetta RL, Scott MM, Zhu JJ. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. Genes Dev 2014;28:273–89
  29. Costa L, Spatuzza M, D’Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, et al. Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol Psychiatry 2012;72:924–33
  30. Wang H, Wu LJ, Kim SS, Lee FJS, Gong B, Toyoda H, et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008;59:634–47
  31. Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, et al. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 2010;647:90–6
  32. Hess LG, Fitzpatrick SE, Nguyen DV, Chen Y, Gaul KN, Schneider A, et al. A randomized, double-Blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome. J Dev Behav Pediatr 2016;37:619–28
  33. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 2017;175:133–50
  34. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270–8
  35. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 2018;78:1791–1804
  36. Marinho ALZ, Vila-Verde C, Fogaça M V, Guimarães FS. Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: contribution of 5HT1A receptors and stressful experiences. Behav Brain Res 2015;286:49–56
  37. Almeida V, Levin R, Peres FF, Niigaki ST, Calzavara MB, Zuardi AW, et al. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Prog Neuropsychopharmacol Biol Psychiatry 2013;41:30–5
  38. Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36:1219–26
  39. Scuderi C, Steardo L, Esposito G. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytother Res 2014;28:1007–13
  40. Cheng D, Spiro AS, Jenner AM, Garner B, Karl T. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J Alzheimers Dis 2014;42:1383–96
  41. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97:9561–6
  42. Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 2010;35:1500–9
  43. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012;3:1080
  44. Tartaglia N, Bonn-Miller M, Hagerman R. Treatment of fragile X syndrome with cannabidiol: a case series study and brief review of the literature. Cannabis Cannabinoid Res 2019;4:3–9
  45. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J pharmacol 2011;162:584–96
  46. Bagni C, Zukin RS. A synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron 2019;101:1070–88
  47. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002;99:7746–50
  48. Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 2010;30:5724-9
  49. Melis M, Greco B, Tonini R. Interplay between synaptic endocannabinoid signaling and metaplasticity in neuronal circuit function and dysfunction. Eur J Neurosci 2014;39:1189–201
  50. Van der Aa N, Kooy RF. GABAergic abnormalities in the fragile X syndrome. Eur J Paediatr Neurol 2020;24:100-104
  51. Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol Res 2017;119:358–70
  52. Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 2008;199:223–30
  53. Norris C, Loureiro M, Kramar C, Zunder J, Renard J, Rushlow W, et al. Cannabidiol modulates fear memory formation through interactions with serotonergic transmission in the mesolimbic system. Neuropsychopharmacology 2016;41:2839–50
  54. Bergamaschi MM, Queiroz RHC, Zuardi AW, Crippa JAS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011;6(4):237–49
  55. Anciones C, Gil-Nagel A. Adverse effects of cannabinoids. Epileptic Disord 2020;22:29–32
  56. McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, et al. A prospective open-label trial of a CBD/THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol 2018;5:1077–88
  57. Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia 2019;60(2):294–302
  58. Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord 2019;11:16
  59. Braat S, D’Hulst C, Heulens I, De Rubeis S, Mientjes E, Nelson DL, et al. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle 2015;14:2985–95
  60. Ligsay A, Van Dijck A, Nguyen DV, Lozano R, Chen Y, Bickel ES, et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. J Neurodev Disord 2017;9:26
  61. Cogram P, Deacon RMJ, Warner-Schmidt JL, von Schimmelmann MJ, Abrahams BS, During MJ. Gaboxadol normalizes behavioral abnormalities in a mouse model of fragile X syndrome. Front Behav Neurosci 2019;13:141
  62. Heulens I, D’Hulst C, Van Dam D, De Deyn PP, Kooy RF. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res 2012;229:244–9
  63. Pacey LKK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 2009;76:18–24
  64. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 2012;4:152ra128
  65. Qin M, Huang T, Kader M, Krych L, Xia Z, Burlin T, et al. R-Baclofen reverses a social behavior deficit and elevated protein synthesis in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 2015;18:pii:pyv034
  66. Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord 2017;9:3
  67. Telias M. Molecular mechanisms of synaptic dysregulation in fragile X syndrome and autism spectrum disorders. Front Mol Neurosci 2019;12:51
  68. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27:370–7
  69. Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, et al. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 2014;23:125–34
  70. Vranesic I, Ofner S, Flor PJ, Bilbe G, Bouhelal R, Enz A, et al. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg Med Chem 2014;22:5790–803
  71. Gantois I, Pop AS, de Esch CEF, Buijsen RAM, Pooters T, Gomez-Mancilla B, et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 2013;239:72–9
  72. Pop AS, Levenga J, de Esch CEF, Buijsen RAM, Nieuwenhuizen IM, Li T, et al. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/mavoglurant. Psychopharmacology (Berl) 2014;231:1227–35
  73. Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J, et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med 2016;8:321ra5
  74. Hagerman R, Jacquemont S, Berry-Kravis E, Des Portes V, Stanfield A, Koumaras B, et al. Mavoglurant in fragile X syndrome: results of two open-label, extension trials in adults and adolescents. Sci Rep 2018;8:16970
  75. Osterweil EK, Chuang S-C, Chubykin AA, Sidorov M, Bianchi R, Wong RKS, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013;77:243–50
  76. Muscas M, Louros SR, Osterweil EK. Lovastatin, not simvastatin, corrects core phenotypes in the fragile X mouse model. eNeuro 2019;6:pii:ENEURO.0097-19.2019
  77. Çaku A, Pellerin D, Bouvier P, Riou E, Corbin F. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A 2014;164A:2834–42
  78. Mason BJ, Heyser CJ. Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 2010;9:23–32
  79. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol 2014;77:315–23
  80. Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, et al. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res 2014;59:220–8
  81. Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013;228:75–84
  82. Salcedo-Arellano MJ, Lozano R, Tassone F, Hagerman RJ, Saldarriaga W. Alcohol use dependence in fragile X syndrome. Intractable Rare Dis Res 2016;5:207–13
  83. Sabus A, Feinstein J, Romani P, Goldson E, Blackmer A. Management of self-injurious behaviors in children with neurodevelopmental disorders: a pharmacotherapy overview. Pharmacotherapy 2019;39:645–64
  84. Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, et al. Open-label riluzole in fragile X syndrome. Brain Res 2011;1380:264–70
  85. Lu XC, Chen RW, Yao C, Wei H, Yang X, Liao Z, et al. NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. J Neurotrauma 2009;26:141–54
  86. Ioudina M, Uemura E. A three amino acid peptide, Gly-Pro-Arg, protects and rescues cell death induced by amyloid beta-peptide. Exp Neurol 2003;184:923–9
  87. Guan J, Thomas GB, Lin H, Mathai S, Bachelor DC, George S, et al. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology 2004;47:892–903
  88. Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology 2019;92:e1912–25
  89. Deacon RMJ, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, et al. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med 2015;17:71–82
  90. Kesler SR, Lightbody AA, Reiss AL. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet A. 2009;149A:403–7
  91. Bruno JL, Hosseini SH, Lightbody AA, Manchanda MK, Reiss AL. Brain circuitry, behavior, and cognition: a randomized placebo-controlled trial of donepezil in fragile X syndrome. J Psychopharmacol 2019;33:975–85

Last update:

No citation recorded.

Last update:

No citation recorded.